Влияние антидисбиотических препаратов на состояние печени крыс с экспериментальным неалкогольным стеатогепатитом

Abstract

The objective: To determine therapeutic and preventive effectiveness o f anti-dysbiotic drugs in experimental steatohepatitis. Materials and methods: Steatohepatitis was reproduced in rats by a combination of high-fat food with llincomycin. As antidysbiotic drugs (ADD) oral phytogels "Quertulidon" (contains quercetin, inulin, imudon, calcium citrate) and "Symbiter" (contains probiotic bacteria and acetic acid yeast) were used. In hepatic homogenate MDA, triglycerides (TGO and cholesterol, elastase activity, urease, lysozyme, alkaline phosphatase (ALP)) were determined. ALT (alanine minotransferase), ALP, TG and cholesterol were determined in the blood serum. Results: Steatohepatitis causes an increase in the triglyceride and cholesterol levels in liver and blood serum, which is reduced after ADD applications. Steatohepatitis increases the levels of inflammatory markers (MDA and elastase) in liver and blood serum . ADD reduce the level o f MDA and, to a lesser extent, reduce the elastase activity. Steatohepatitis increases ALT and ALP in blood. ADD slightly reduce their level. Steatohepatitis enhances the urease activity in the liver and reduces the activity o f lysozyme in liver. Conclusion: In the pathogenesis o f steatohepatitis dysbiosis plays a significant role, the extent o f dysbiosis can be reduced by oral ADD administrations. Высокожировая диета в сочетании с введением линкомицина вызывает развитие стеатогепатита. Введение антидисбиотических средств (про- и пребиотиков) оказывает лечебно-профилактический эффект. Високожирова дієта в сполученні з введенням лінкоміцина викликають розвичних засобів (про- і пребіотиків) здійснює лікувально-профілаткичний ефект.